The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 03, 2021

Filed:

May. 20, 2015
Applicants:

Amgen Research (Munich) Gmbh, Munich, DE;

Amgen Inc., Thousand Oaks, CA (US);

Inventors:

Gerhard Zugmaier, Munich, DE;

Peter Kufer, Munich, DE;

Shilpa Alekar, San Diego, CA (US);

Assignees:

AMGEN RESEARCH (MUNICH) GMBH, Munich, DE;

AMGEN INC., Thousand Oaks, CA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/28 (2006.01); G01N 33/574 (2006.01); G01N 33/50 (2006.01); A61K 35/17 (2015.01); A61K 38/17 (2006.01); A61K 35/12 (2015.01);
U.S. Cl.
CPC ...
G01N 33/57426 (2013.01); A61K 35/17 (2013.01); A61K 38/1774 (2013.01); C07K 16/2803 (2013.01); C07K 16/2809 (2013.01); G01N 33/5091 (2013.01); A61K 2035/124 (2013.01); C07K 2317/31 (2013.01); C07K 2317/622 (2013.01); G01N 2333/70503 (2013.01); G01N 2800/50 (2013.01); G01N 2800/52 (2013.01); G01N 2800/56 (2013.01);
Abstract

The present invention relates to a method for risk-stratifying subjects suffering from B-precursor acute lymphoblastic leukemia (ALL), wherein said subjects are intended for a therapy comprising administration of a CD3 binding domain. Risk-stratification is based on the determination of the amount blast cells in a bone marrow sample from said subject, and/or on the determination of the number of blast cells per 1 μl in a CSF sample from said subject. According to the category into which subjects are risk-stratified, said subjects can be appropriately treated, while their risk of a potential adverse neurological reaction can be reduced or even excluded.


Find Patent Forward Citations

Loading…